{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T03:06:16Z","timestamp":1792465576863,"version":"4.5.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["journalofclinicalvirology.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Virology"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.jcv.2016.11.009","type":"journal-article","created":{"date-parts":[[2016,11,23]],"date-time":"2016-11-23T01:35:45Z","timestamp":1479864945000},"page":"27-30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Evaluation of the inactivation effect of Triton X-100 on Ebola virus infectivity"],"prefix":"10.1016","volume":"86","author":[{"given":"Francesca","family":"Colavita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Quartu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Lalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Licia","family":"Bordi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Lapa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Meschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Vulcano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonietta","family":"Toffoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Bordi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Paglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Di Caro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Ippolito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rosaria","family":"Capobianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concetta","family":"Castilletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcv.2016.11.009_bib0005","unstructured":"World Health Organization. Ebola response roadmap \u2212situation report. WHO Geneva. Available at (accessed July, 2016): http:\/\/apps.who.int\/ebola\/ebola-situation-reports."},{"key":"10.1016\/j.jcv.2016.11.009_bib0010","unstructured":"Centers for Disease Control and Prevention. Interim guidance for specimen collection, transport, testing, and submission for persons under investigation for Ebola virus disease in the United States. (accessed July, 2016). http:\/\/www.cdc.gov\/vhf\/ebola\/healthcare-us\/laboratories\/specimens.html."},{"issue":"Suppl. 1","key":"10.1016\/j.jcv.2016.11.009_bib0015","article-title":"Canadian contingency plan for viral hemorrhagic fevers and other related diseases","volume":"23","author":"Public Health Agency of Canada","year":"1997","journal-title":"Can. Commun. Dis. Rep."},{"issue":"2","key":"10.1016\/j.jcv.2016.11.009_bib0020","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1006\/biol.2000.0245","article-title":"A tritonX-100-split virion influenza vaccine is safe and fulfills the committee for proprietary medicinal products (CPMP) recommendations for the european community for immunogenicity, in children, adults and the elderly","volume":"28","author":"Lina","year":"2000","journal-title":"Biologicals"},{"key":"10.1016\/j.jcv.2016.11.009_bib0025","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1007\/BF01962603","article-title":"Inactivation of human immunodeficiency virus in serum specimens as a safety measure for diagnostic immunoassays","volume":"7","author":"Ukkonen","year":"1988","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.jcv.2016.11.009_bib0030","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0378-1135(86)90005-2","article-title":"Resistance of Berne virus to physical and chemical treatment","volume":"11","author":"Weiss","year":"1986","journal-title":"Vet. Microbiol."},{"issue":"5","key":"10.1016\/j.jcv.2016.11.009_bib0035","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1128\/AEM.03580-14","article-title":"Mechanism of method for Hepatitis C virus inactivation","volume":"81","author":"Pfaender","year":"2015","journal-title":"Appl. Environ. Microbiol."},{"key":"10.1016\/j.jcv.2016.11.009_bib0040","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1046\/j.1365-2362.1999.00462.x","article-title":"Long-term stability of human immunodeficiency virus viral load and infectivity in whole blood","volume":"29","author":"Vandamme","year":"1999","journal-title":"Eur. J. Clin. Invest."},{"issue":"October (10)","key":"10.1016\/j.jcv.2016.11.009_bib0045","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1128\/JCM.00346-16","article-title":"Rapid bedside inactivation of Ebola virus for safe nucleic acid tests","volume":"54","author":"Rosenstierne","year":"2016","journal-title":"J. Clin. Microbiol."},{"issue":"7","key":"10.1016\/j.jcv.2016.11.009_bib0050","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.3201\/eid2207.160233","article-title":"Effective chemical inactivation of Ebola virus","volume":"22","author":"Haddock","year":"2016","journal-title":"Emerg. Infect. Dis."},{"issue":"Suppl. 3","key":"10.1016\/j.jcv.2016.11.009_bib0055","doi-asserted-by":"crossref","first-page":"S218","DOI":"10.1093\/infdis\/jiw289","article-title":"Inactivation of Zaire Ebolavirus variant Makona in human serum samples analyzed by enzyme-linked immunosorbent assay","volume":"214","author":"Cutts","year":"2016","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jcv.2016.11.009_bib0060","first-page":"493","article-title":"A simple method of estimating fifthy percent end-points","volume":"27","author":"Reed","year":"1938","journal-title":"Am. J. Hyg."},{"key":"10.1016\/j.jcv.2016.11.009_bib0065","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1111\/j.1537-2995.2009.02222.x","article-title":"Robustness of solvent\/detergent treatment of plasma derivatives: a data collection from Plasma Protein Therapeutics Association member companies","volume":"49","author":"Dichtelm\u00fcller","year":"2009","journal-title":"Transfusion"},{"key":"10.1016\/j.jcv.2016.11.009_bib0070","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1373\/clinchem.2004.031666","article-title":"Influence of practicable virus inactivation procedures on tests for frequently measured analytes in plasma","volume":"50","author":"Hersberger","year":"2004","journal-title":"Clin. Chem."},{"issue":"12","key":"10.1016\/j.jcv.2016.11.009_bib0075","first-page":"1967","article-title":"Diagnostic Performances of clinical laboratory tests using TritonX-100 to reduce the biohazard associated with routine testing of Ebola Virus-infected patients","volume":"53","author":"Tempestilli","year":"2015","journal-title":"Clin. Chem."},{"key":"10.1016\/j.jcv.2016.11.009_bib0080","article-title":"A feasibility study on the effects of Triton X-100 for the in vitro inactivation of Ebola virus on haematological assays","author":"Mifsud","year":"2015","journal-title":"J. Clin. Pathol."},{"issue":"6","key":"10.1016\/j.jcv.2016.11.009_bib0085","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1086\/314524","article-title":"Effects of viral hemorrhagic fever inactivation methods on the performance of rapid diagnostic test for Plasmodium falciparum","volume":"178","author":"Loufty","year":"1998","journal-title":"J. Infect. Dis."},{"issue":"4","key":"10.1016\/j.jcv.2016.11.009_bib0090","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1128\/JCM.00165-15","article-title":"Evaluation of Ebola virus inactivation procedures for Plasmodium falciparum Malaria Diagnostics","volume":"53","author":"Lau","year":"2015","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.jcv.2016.11.009_bib0095","unstructured":"Horowitz B., Prince A.M., Horowitz M.S., Watklevicz C., Virus safety of solvent-detergent treated blood products. In: Brown F, editor. Virological safety aspects of plasma derivatives. Dev Biol Stand. 1993. 81:147-61. Basel: Karger"},{"key":"10.1016\/j.jcv.2016.11.009_bib0100","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/BF01703243","article-title":"Ultrapure plasma factor VIII produced by anti F VIIIc immunoaffinity chromatography and solvent\/detergent viral inactivation. Characterization of the Method M process and Hemofil M antihemophilic factor (human)","volume":"63","author":"Griffith","year":"1991","journal-title":"Ann. Hematol."}],"container-title":["Journal of Clinical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653216306047?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653216306047?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T13:26:31Z","timestamp":1536240391000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1386653216306047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":20,"alternative-id":["S1386653216306047"],"URL":"https:\/\/doi.org\/10.1016\/j.jcv.2016.11.009","relation":{},"ISSN":["1386-6532"],"issn-type":[{"value":"1386-6532","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of the inactivation effect of Triton X-100 on Ebola virus infectivity","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcv.2016.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}